Clinical Trial

Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Study acronym: SKB264-Fru-GA
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 multicenter study that will evaluate the safety and efficacy of sacituzumab tirumotecan (Sac-TMT) plus fruquintinib for the treatment of participants with locally advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma who have failed 1 prior line of therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-07.
Trial Details
NCT Number NCT07689292
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Collaborators: Peking Union Medical College Hospital
Conditions Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
Enrollment 45 participants
Start Date 2026-07-31
Primary Completion 2027-08-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-09